Evidence map›Paper›PMID 39726776›Full record

ArticleFrontiers in pharmacology2024

Macranthoidin B restrains the epithelial-mesenchymal transition through COX-2/PGE

Yi Ding, Xiaoqian Yang, Qinghua Wei, Xuanming Bi, Yuxin Zhang, Yuxia Ma, Meisen Yang, Xiaoyu Xu, Cong Li, Qin Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi Ding *School of Chinese Materia Medica, Chongqing University of Chinese Medicine, Chongqing, China.
Xiaoqian Yang *College of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, China.
Qinghua Wei *College of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, China.
Xuanming BiCollege of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, China.
Yuxin ZhangCollege of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, China.
Yuxia MaCollege of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, China.
Meisen YangTraditional Chinese Medicine Industry Center of Xiushan Tujia & Miao Autonomous County, Agriculture and Rural Affairs Committee of Xiushan Tujia & Miao Autonomous County, Chongqing, China.
Xiaoyu XuCollege of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing, China.
Cong LiDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qin WangDepartment of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Yi ChenSchool of Chinese Materia Medica, Chongqing University of Chinese Medicine, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Macranthoidin B is one of the primary and unique triterpenoid saponin metabolites from Methods: Using rat autograft EMS model, the volume of ectopic endothelium, the histopathology, serum E Results: In a rat autograft EMS model, macranthoidin B suppressed ectopic lesion volume, improved histopathological morphology, and regulated serum estradiol (E2) and progesterone (PROG) levels. Additionally, macranthoidin B inhibited invasion and metastasis of primary endometriotic stromal cells and HEC1-B cells. Mechanistically, macranthoidin B suppressed COX-2/PGE Discussion: Macranthoidin B prevents epithelial-mesenchymal transition through COX-2/PGE2 pathway in EMS. It will facilitate the macranthoidin B's development and broaden its potential application.

Indexed as

COX-2/PGE2 pathwayendometriosisepithelial-mesenchymal transitioninvasion and metastasismacranthoidin B

Identifiers

PMID39726776
PMCPMC11669684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.